Kleber Gomes Franchini; Mario Jose Abdalla Saad; Roberto Rittner Neto; Rodrigo Miguel Marin; Aparecida Silvana Rocco
The present invention introduces compounds that are adenosine-kinase inhibitors. We provide a process of protecting tissues and organs like heart, brain and kidneys affected by ischemia, and of treating heart insufficiency, myocardium infarct, arrhythmia, arterial hypertension, atherosclerosis, coronary artery re-stenosis after angioplasty, chronic renal insufficiency, cerebral vascular accident, and chronic inflammatory diseases (e.g. rheumatoid arthritis). We also provide the adenosine-kinase inhibitor effect of compounds derived from quinazolines, which were previously known as reversible inhibitors of tyrosine-kinases from the family of epidermic growth factor receptors (EGFR).